Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 06/07

20070149762 - Block copolypeptide vesicle based materials for drug delivery: In some embodiments, the present invention is directed to block copolypeptides comprising lysine and glycine. In other embodiments, the present invention is directed to a method for reversibly forming supramolecular structures from block copolypeptides. In further embodiments, the present invention is directed to covalently cross-linked supramolecular structures formed from block... Agent: Winstead Sechrest & Minick P.C.

20070149761 - Hcv rna dependent rna polymerase: The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.... Agent: Merck And Co., Inc

20070149763 - Beta secretase exosite binding peptides and methods for identifying beta secretase modulators: The present invention provides the crystal structure of BACE-1 complexed with both an active site inhibitor and an exosite peptide containing the core sequence YPYFI. The crystal structure shows the exosite peptide bound to the BACE-1 exosite and identifies a novel peptide binding site on the surface of the BACE-1.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070149765 - Liquid phase peptide syntheses of kl-4 pulmonary surfactant: The invention realtes to improved liquid phase processes for the preparation of the 21 residue protein component, (Lys-Leu4)4-Lys, of the pulmonary surfactant KL-4. These process are amenable to large scale synthesis and one process employs a method of saponifying an ester which reduces the inherent racemization of the α-carbon.... Agent: Philip S. Johnson Johnson & Johnson

20070149764 - Polypeptide having collagen-like structure: wherein X and Y each represent any amino acid residue are tethered to one another such that they are shifted relative to one another in the backbone direction. The peptide trimer is capable of forming a polypeptide having a collagen-like triple helix structure. A method of producing the peptide trimer... Agent: Birch Stewart Kolasch & Birch

20070149766 - Method for producing a recombinant protein of interest and protein thus produced: A fragment of an alpha-integrin for producing at least one recombinant protein of interest in a cell, with the exception of a mammalian cell.... Agent: Ip Group Of Dla Piper US LLP

20070149767 - Agent: An agent having a greater half-life than naturally produced albumin in a patient with NS, the agent comprising an albumin-like first polypeptide bound to a second polypeptide, wherein the second polypeptide, when bound to the albumin-like first polypeptide is therapeutically inert and wherein if the agent consists of two albumin... Agent: Synnestvedt & Lechner, LLP

20070149769 - Endothelial cell-leukocyte adhesion molecules (elams) and molecules involved in leukocyte adhesion (milas): Antibodies specific for ELAMs are disclosed.... Agent: Fish & Richardson

20070149768 - Specific human antibodies for selective cancer therapy: The present invention is directed to a peptide or polypeptide comprising an Fv molecule, a construct thereof, a fragment of either, or a construct of a fragment having enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the binding... Agent: Kenyon & Kenyon LLP

20070142622 - Peptide epitopes recognized by disease promoting cd4+ t lymphocytes: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide... Agent: Fish & Richardson PC

20070142623 - Protein expression system: The present invention relates to a method of producing a target protein, which method comprises expressing said protein in a host cell which contains a nucleic acid molecule which encodes a chimeric protein, said chimeric protein comprising a signal peptide from a non-mammalian bulk-secreted protein and said target protein; nucleic... Agent: Needle & Rosenberg, P.C.

20070142624 - Purification method for recombinant glucose binding protein: Methods for obtaining recombinant glucose binding proteins are provided. In particular methods for obtaining Concanavalin A are described. The use of the proteins in systems, e.g. for glucose determini ation are also provided.... Agent: Brooks Kushman P.C.

20070142625 - Virus filtration of liquid factor vii compositions: The present invention relates to a novel method for improving the viral safety of liquid Factor VII compositions, in particular those comprising active Factor VII polypeptides (a Factor VIIa polypeptide).... Agent: Novo Nordisk, Inc. Patent Department

20070142626 - Cross-linking reagents for hemoglobin and hemoglobin products cross-linked therewith: A process for efficiently preparing bis-tetrameric hemoglobin in which the tetramers are specifically linked at predetermined sites on the β-sub-units and in which the tetramers themselves are effectively bonded to prevent dissociation into dimeric αβ-hemoglobin sub-units therefrom is provided. The process uses as cross-linking reagent a hexafunctional aromatic acyl phosphate... Agent: Burns & Levinson, LLP

20070142627 - Sugar-chain-altered anti-hm1.24 antibody: An antibody (anti-HM1.24 antibody) against HM1.24 antigen in which the alteration of sugar chains resulted in enhanced antibody-dependent cellular cytotoxicity (ADCC), specifically an antibody having a sugar chain that does not contain α-1,6 core fucose, an antibody having a sugar chain that contains a bisecting N-acetylglucosamine (GlcNAc) structure, or an... Agent: Foley And Lardner LLP Suite 500

20070142628 - 6-monoacetylmorphine derivatives useful in immunoassay: Analogs of 6-monoacetyl morphine (6-MAM) are described. These include analogs derivatized at either the C-3 position, the C-6 position, or the nor position of the molecule. These analogs allow for elaboration with linkers terminated by a functional group such as an activated ester, the functional groups being useful for attaching... Agent: Roche Diagnostics Operations Inc.

20070142629 - Multichemistry fractionation: Methods, apparatuses, and kits for fractionating complex mixtures of biological molecules are provided. In one aspect the methods provided include providing a series of different sorbents, introducing the complex mixture to the series of sorbents, contacting serially the complex mixture with each of the sorbents, and capturing biomolecular components from... Agent: Ciphergen C/o Foley & Lardner LLP

20070135618 - Peptide epitopes recognized by disease promoting cd4+ t lymphocytes: The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide... Agent: Fish & Richardson PC

20070135619 - Production of a von willebrand factor prepartion having a great specific activity: This invention relates to a process for the production of a von Willebrand factor preparation having a high specific activity, hydroxylapatite being used as a chromatography medium.... Agent: Smith Patent Consulting Consulting, LLC

20070135620 - Fc variants with altered binding to fcrn: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.... Agent: Robin M. Silva, Esq. Dorsey & Whitney LLP

20070135621 - Therapeutic products with enhance ability to immunomodulate cell functions: The present invention relates to a method for the production and the selection of human or chimaeric or humanized antibodies or molecules that comprise the Fc region of human IgG, capable of modulating the activity of one or several particular Fc receptors, such as the triggering of inhibitory functions through... Agent: Foley And Lardner LLP Suite 500

20070135622 - Method and apparatus for manufacturing lignophenol derivative: It is an object to provide a method in which a lignocellulosic material is treated with a phenol derivative and an acid, whereby a lignophenol derivative can be produced and recovered efficiently, and moreover sugar from an acid/sugar mixture obtained at the same time can be recovered and used easily.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070129537 - Synthesis of peptide alpha-thioesters: Disclosed herein is a new method for the solid phase peptide synthesis (SPPS) of C-terminal peptide α thioesters using Fmoc/t-Bu chemistry. This method is based on the use of an aryl hydrazine linker, which is totally stable to conditions required for Fmoc-SPPS. When the peptide synthesis has been completed, activation... Agent: Ann M. Lee Assistant Laboratory Counsel

20070129538 - Cytokine protein family: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral... Agent: Zymogenetics, Inc. Intellectual Property Department